A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy

Medicine and Dentistry

1. Patient 100%
2. Acute Leukemia 100%
3. Lymphoblastic Lymphoma 100%
4. Phenotype 100%
5. Therapeutic Procedure 100%
6. Inotuzumab Ozogamicin 100%
7. Disease Free Survival 50%
8. Chemotherapy 50%
9. Lymphoid Leukemia 25%
10. Spine 25%
11. Oncology 25%
12. Age 25%
13. Event Free Survival 25%
14. Maintenance Therapy 25%
15. Child 25%